QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Voloschin, A. D. Articles by Batchelor, T. T. Search for Related Content PubMed PubMed Citation

Neoadjuvant temozolomide followed by complete resection of a 1p- and 19q-deleted anaplastic oligoastrocytoma: Case study

Departments of Neurology (A.D.V., T.T.B.), Pathology (D.N.L.), and Neurosurgery (D.N.L., G.R.C.) and Cancer Center (D.N.L.), Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA

² Address correspondence to Tracy Batchelor, Brain Tumor Center, Cox 315, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA (tbatchelor{at}partners.org).

Abstract

A 38-year-old woman presented with an infiltrative tumor of the right frontal lobe and genu of the corpus callosum that was deemed only partially resectable. A stereotactic biopsy was performed, which revealed a right frontal oligoastrocytoma that had some anaplastic features as well as allelic loss of chromosome arms 1p and 19q. The patient was treated with temozolomide for 24 months. The partial response of the tumor to chemotherapy rendered the lesion amenable to gross total resection, which was performed subsequently. The patient remains alive and well without evidence of recurrence 7 months after resection and 48 months after initial diag-nosis. Thus, preoperative chemotherapy decreased tumor mass to a degree that subsequently enabled a gross total resection. This treatment strategy, although common in the treatment of other solid tumors, is rarely utilized in adult neuro-oncology and raises another potential role for chromosome testing in oligodendroglial tumor management.

This article has been cited by other articles:

				G. Kaloshi, A. Benouaich-Amiel, F. Diakite, S. Taillibert, J. Lejeune, F. Laigle-Donadey, M.-A Renard, W. Iraqi, A. Idbaih, S. Paris, et al. Temozolomide for low-grade gliomas: Predictive impact of 1p/19q loss on response and outcome Neurology, May 22, 2007; 68(21): 1831 - 1836. [Abstract] [Full Text] [PDF]